Science Explorer Back to mapMap
Discussion
Topic · Neurology

CNS Lymphoma Diagnosis and Treatment

CNS Lymphoma Diagnosis and Treatment is a research topic within Neurology. Science Explorer counts 17k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the diagnosis, treatment, and management of primary central nervous system lymphoma (PCNSL). It covers various aspects such as prognostic scoring systems, chemotherapy and radiotherapy regimens, use of methotrexate and rituximab therapy, genetic features, neurological masquerade syndromes, and cognitive functions in PCNSL patients.

  • Primary CNS Lymphoma
  • Prognostic Scoring System
  • Chemotherapy
  • Radiotherapy
  • Methotrexate
  • Intravascular Lymphoma
  • Rituximab Therapy
  • Genetic Features
  • Neurological Masquerade Syndromes
  • Cognitive Functions
Research works
17k
fractional, since 1950
In the world top 10%
1.7k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+18%
the tick is no change
Largest producer
United States
34% of the 10 largest, 2022-now
CNS Lymphoma Diagnosis and Treatment

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead CNS Lymphoma Diagnosis and Treatment research?

By volume, the United States and China publish the most (1k and 700 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1k works
  2. 2 China 700 works
  3. 3 Japan 324 works
  4. 4 India 190 works
  5. 5 Germany 158 works
  6. 6 France 147 works
  7. 7 Italy 134 works
  8. 8 United Kingdom 100 works
  9. 9 Türkiye 92 works
  10. 10 Spain 91 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 34.1%China: 23.8%Japan: 11.0%India: 6.5%6 others listed: 24.6%34%largest
United States1,003 · 34.1%China700 · 23.8%Japan324 · 11.0%India190 · 6.5%6 others listed723 · 24.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead CNS Lymphoma Diagnosis and Treatment research?

By volume in 2022-now, Capital Medical University publishes the most CNS Lymphoma Diagnosis and Treatment research, followed by Mayo Clinic and Harvard University.

Who are the leading researchers in CNS Lymphoma Diagnosis and Treatment?

The most-cited researchers publishing on CNS Lymphoma Diagnosis and Treatment include Robert John Tibshirani, Gad A. Getz and Jost Bruno Jonas.

  1. 1 Robert John Tibshirani United States 396k citations
  2. 2 Gad A. Getz United States 364k citations
  3. 3 Jost Bruno Jonas Germany 350k citations
  4. 4 Matthias Egger Switzerland 326k citations
  5. 5 Hagop M. Kantarjian United States 273k citations
  6. 6 Carlo La Vecchia Italy 258k citations
  7. 7 Kaj Blennow Sweden 247k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in CNS Lymphoma Diagnosis and Treatment?

The most cited paper in CNS Lymphoma Diagnosis and Treatment is "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" (Bruce D. Cheson, Richard I. Fisher, Sally Fiona Barrington et al., 2014), with 5,725 citations. Next come "Revised Response Criteria for Malignant Lymphoma" (4,468) and "The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma" (3,883).

Most cited papers
#PaperReleasedCitations
1 Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification Bruce D. Cheson, Richard I. Fisher, Sally Fiona Barrington et al. · Journal of Clinical Oncology Open access 11 Aug 2014 5,725
2 Revised Response Criteria for Malignant Lymphoma Bruce D. Cheson, Beate Pfistner, Malik Eid Juweid et al. · Journal of Clinical Oncology Open access 22 Jan 2007 4,468
3 The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma Andreas Rosenwald et al. · New England Journal of Medicine Open access 20 Jun 2002 3,883
4 WHO-EORTC classification for cutaneous lymphomas Rein Willemze · Blood Open access 3 Feb 2005 3,826
5 VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA M. Anthony Epstein, B. G. Achong, Y. M. Barr · The Lancet Mar 1964 2,797
All 100 most cited papers, with filters and sorting

Where is CNS Lymphoma Diagnosis and Treatment research done?

The largest centres of CNS Lymphoma Diagnosis and Treatment research in 2022-now are Beijing (China), Tokyo (Japan), New York (United States) and Shanghai (China).

Largest cities, 2022-now

  1. 1 BeijingChina 147 works
  2. 2 TokyoJapan 74 works
  3. 3 New YorkUnited States 67 works
  4. 4 ShanghaiChina 65 works
  5. 5 ParisFrance 60 works
  6. 6 HoustonUnited States 46 works
  7. 7 SeoulSouth Korea 42 works
  8. 8 GuangzhouChina 39 works
  9. 9 LondonUnited Kingdom 38 works
  10. 10 PhiladelphiaUnited States 36 works
See CNS Lymphoma Diagnosis and Treatment on the map

Where is the best place to study CNS Lymphoma Diagnosis and Treatment?

Among universities, judged by research, Capital Medical University, Harvard University and University of Toronto score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 18.44%fractional works in this field (log) →share of work in the world top 10% →University of TorontoUniversity of MiamiHarvard UniversityCapital Medical Univ…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Capital Medical UniversityChina 68.111.4%15.5×56 +102.4%
2Harvard UniversityUnited States 66.517.7%3.2×34 -20.6%
3University of TorontoCanada 61.624.9%1.8×12 +51.4%
4University of MiamiUnited States 60.921.3%6.9×14 -3.9%
5Heidelberg UniversityGermany 60.921.9%4.1×11 +38.7%
6Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 57.99.9%8.4×30 +88.6%
7Shanghai Jiao Tong UniversityChina 57.318.2%2.4×23 +80.3%
8Cornell UniversityUnited States 57.122.7%3.2×14 -25.2%
9University College LondonUnited Kingdom 56.518.8%2.2×12 +8.3%
10Université Paris CitéFrance 55.617.6%5.5×14 +2.7%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in CNS Lymphoma Diagnosis and Treatment, country by country

Is CNS Lymphoma Diagnosis and Treatment research growing?

Output in 2022-2025 was 18% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are CNS Lymphoma Diagnosis and Treatment.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is CNS Lymphoma Diagnosis and Treatment as a percentage of every work published that year, 0.014% in 2024.

still counting0.010%0.020%CNS Lymphoma Diagnosis and Treatment0.018% in 202519801990200020102020

Fractional works of CNS Lymphoma Diagnosis and Treatment over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%CNS Lymphoma Diagnosis and Treatment10.4% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about CNS Lymphoma Diagnosis and Treatment. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.